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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A392Analogue Scale (VAS), and the Range of Motion (ROM) was measured
using a digital goniometer. The Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) and ascending-descending
stairs time were used to assess function.
Results:Mean age and body mass index (BMI) of our study group were,
respectively, 54.7±6.8 years and 31.3±5.1 kg/m2 in the MWM group and
54.6±7.3 years and 30.5±4.2 kg/m2 in the PJM group. There was no
signiﬁcant difference between groups in respect of age and BMI
(p>0.05). Both groups had signiﬁcant decreases in pain according to the
VAS (p<0.05). The ROM values and function level signiﬁcantly improved
within both groups (p<0.05). There was no statistically signiﬁcant dif-
ference in pain (p¼0.13), knee ﬂexion (p¼0.77), knee extension ROM
(p¼0.43), WOMAC scores (p¼0.65) and ascending-descending stairs
time (p¼0.06) between the two groups before and after the treatment.
Conclusions: The results indicate that patients with osteoarthritis of
the knee gain clinically beneﬁt from mobilization techniques on pain,
ROM and function. Therefore, we suggest that physiotherapist either
can apply MWM or PJM techniques based on their clinical experience in
the management of osteoarthritis of the knee. This work was supported
by University, Scientiﬁc Research Projects (Number:30150)
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EFFECTS OF 8-WEEK WHOLE-BODY VIBRATION TRAINING ON KNEE
EXTENSORS STRENGTH IN HEALTHY YOUNG VOLUNTEERS
S. Esmaeilzadeh, M. Akpinar, S.E. Polat, A. Yildiz, A. Oral. Istanbul Univ.
Istanbul Faculty of Medicine, Istanbul, Turkey
Purpose: Knee extensor muscle weakness increases the risk of different
knee disorders including knee osteoarthritis. The aim of present study
was to determine the effects of 8 weeks whole-body vibration training
(WBVT) program on the strength of knee extensor muscles in untrained
volunteers.
Methods: Twenty eligible healthy untrained youngwomen volunteered
to participate in a supervised 8 weeks WBVT program that consisted of
24 sessions on vibration platform (30- Hz, 2-6 mm, 2-3 positions, 2-24
sets) three times per week for 8 weeks. Isometric and dynamic strength
of the knee extensor muscles were measured prior to and at the end of
the 8-week training.
Results: There was a signiﬁcant increase in the maximal voluntary
isometric contraction (p¼0.046) at the end of the 8-week training. In
addition, both concentric (p¼0.004) and eccentric (p¼0.031) peak tor-
ques of knee extensors increased signiﬁcantly after 8 weeks training.
Conclusions: These results suggest that 8 weeks WBVT is an effective
training method for improving the strength knee extensors in young
healthy women.
Therapy: Pharmacologic
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INTRA-ARTICULAR CORTICOSTEROIDS MAY BE A COST-EFFECTIVE
STRATEGY FOR SHORT-TERM MANAGEMENT OF KNEE
OSTEOARTHRITIS
R.R. Bannuru y, J.B. Wong y, D.M. Kent y, C.H. Schmid z, T.E. McAlindon y.
y Tufts Med. Ctr., Boston, MA, USA; zBrown Univ., Providence, RI, USATable 1
Model Inputs
Acetaminophen Diclofenac Ibuprofen
Dosage (mg/day) 3000 150 2400
Total WOMAC Change
from Baseline* [95% CrI]
16.07
[13.68-18.46]
22.7
[20.04-25.36]
21.17
[18.42-23.92]
Total Cost (USD)/3 mo [SD] 33.33 [8.65] 268.64 [59.15] 117.32 [27.47]
3-month Adverse Event
Probabilities (%) [SD]
GI Distress 14.46 [0.54] 24.05 [0.90] 14.46 [0.54]
Symptomatic Ulcer 0.07 [0.03] 0.14 [0.02] 0.20 [0.09]
Complicated Ulcer 0.03 [0.02] 0.07 [0.01] 0.08 [0.04]
Myocardial Infarction 0.07 [0.03] 0.09 [0.01] 0.15 [0.11]
Stroke 0.03 [0.02] 0.06 [0.01] 0.06 [0.04]
Local Joint Reaction 0 0 0
Septic Joint 0 0 0
IA ¼ intra-articular; inj ¼ injection; 3 mo ¼ 3 month; WOMAC ¼ Western Ontario and
dollar; GI ¼ gastrointestinal; * Baseline total WOMAC score ¼ 51.17 (15.19).Purpose: The most commonly prescribed treatments for knee osteo-
arthritis (OA) are traditional nonsteroidal anti-inﬂammatory drugs
(NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors. The gastro-
intestinal (GI) and cardiovascular (CV) adverse events associated with
these agents have important quality of life and resource use implica-
tions. While most prior evaluations have compared the use of tradi-
tional NSAIDs with COX-2 inhibitors, none has included injection
therapies such as corticosteroids and hyaluronic acid. Commonly used
injection therapies are relatively free of the GI and CV adverse events
commonly seen with the use of oral therapies. However, since the costs
of some injection therapies are relatively high compared with tradi-
tional NSAIDs, it is unclear whether these treatments are cost-effective.
Therefore, we performed a cost-effectiveness analysis comparing vari-
ous oral and intra-articular (IA) injection therapies for OA over a period
of three months.
Methods: We conducted an economic evaluation using a decision
analytic model (Figure 1). Estimates of cardiovascular (CV) and gas-
trointestinal (GI) adverse events were based on data from three large
pivotal safety trials, and observational data were used for sensitivity
analyses. Treatment efﬁcacy was estimated by performing a network
meta-analysis of the 77 trials reporting total Western Ontario and
McMaster Universities (WOMAC) osteoarthritis index score for these
interventions. Other model inputs were obtained from the relevant
literature (Table 1). The base-case model was run for a hypothetical
patient population with moderate knee OA aged between 55-64 years
with no previous history of GI or CV adverse events. Analyses were
conducted in a high-risk model consisting of patients aged between 65-
74 years who are at a high risk of GI or CV adverse events. We compared
commonly used treatments for which suitable data were available;
these included acetaminophen (3000 mg/day), diclofenac (150 mg/
day), ibuprofen (2400 mg/day), naproxen (1000 mg/day), celecoxib
(200 mg/day), IA corticosteroids, & IA hyaluronic acid (both single
course). The possibility of adding a proton pump inhibitor (PPI) (ome-
prazole 20 mg/day) was also tested. Main outcome measures were
direct costs, quality-adjusted life-years (QALY) gained and incremental
cost-effectiveness ratios (ICER). QALYs were calculated from pooled
estimates of efﬁcacy and major adverse events (i.e. GI distress, symp-
tomatic and complicated ulcer, myocardial infarction, stroke, local joint
reactions, and septic joint).
Results: Our base case analysis showed that IA corticosteroids were the
preferred strategy for a willingness to pay threshold of $3,000 (Table 2;
Figure 2). If a decision maker is willing to pay $25,000, ibuprofen þ PPI
strategy was cost-effective. NSAIDs without PPI co-prescription were
dominated by NSAIDs with PPI (more expensive and less effective).
Compared to the base-case model, the high-risk model featured more
serious adverse events leading to a greater impact on quality of life. This
increase in risk did not change the relative rankings of treatments
compared to the base-case, although the willingness to pay thresholds
increased marginally. NSAIDs without PPI co-prescription were still
dominated in the high-risk model. In both models, we found that it will
cost less than $10,000 to gain a QALY by adding PPIs to NSAIDs.
Conclusions: For a willingness to pay threshold of $3,000, IA cortico-
steroids are the preferred strategy for managing knee OA over a 3-
month period. This result is driven primarily by their substantial efﬁ-
cacy (at least in the short-term) and relatively high level of safety. OurNaproxen Celecoxib IA Corticosteroids IA Hyaluronic Acid
1000 200 1 inj/3 mo 1-5 inj/3 mo
21.35
[19.47-23.23]
19.68
[18.13-21.23]
18.24
[12.43-24.05]
23.73
[18.90-28.56]
241.24 [48.26] 758.12 [100.00] 56.88 [11.00] 1358.47 [105.47]
17.00 [0.43] 14.16 [0.46] 7.52 [0.25] 7.52 [0.25]
0.28 [0.07] 0.09 [0.04] 0.04 [0.02] 0.04 [0.02]
0.07 [0.02] 0.05 [0.03] 0.2 [0.01] 0.2 [0.01]
0.06 [0.03] 0.15 [0.10] 0.06 [0.03] 0.06 [0.03]
0.08 [0.03] 0.03 [0.02] 0.2 [0.01] 0.2 [0.01]
0 0 8.51 [0.87] 13.09 [0.46]
0 0 0.002 [0.001] 0.002 [0.001]
McMaster Universities Arthritis Index; CrI ¼ credible interval; USD ¼ United States
Table 2
Cost-Effectiveness Results of Low-Risk (Base-case) Cohort (55-64 years)
Strategy Per 10,000 people treated Total WOMAC change
from baseline, per patient
ICER ($ per QALY) Comparator
Gastrointestinal
Events*
Cardiovascular
Eventsy
Total Cost
($, 1000s)
Total
QALYs
Acetaminophen 10 10 650 1505 16.07
IACS 6 8 826 1564 18.24 2989 Acetaminophen
Acetaminophen þ PPI‡ 3.55 10 1080 1540 16.07
IACS þ PPI§ 2.12 8 1275 1583 18.24
Ibuprofen§ 28 21 1811 1588 21.17
Ibuprofen þ PPI 9.96 21 2203 1625 21.17 22529 IACS
Naproxen‡ 35 14 2864 1580 21.35
Diclofenac‡ 21 15 3182 1569 22.70
Naproxen þ PPI‡ 12.6 14 3257 1624 21.35
Diclofenac þ PPI 7.42 15 3568 1631 22.70 232593 Ibuprofen þ PPI
Celecoxib‡ 14 18 8113 1567 19.68
Celecoxib þ PPI‡ 3.36 18 8517 1615 19.68
IAHA§ 6 8 13838 1647 23.73
IAHA þ PPI 2.12 8 14287 1667 23.73 303107 Diclofenac þ PPI
$ ¼ US Dollar; PPI ¼ proton pump inhibitor; QALY ¼ quality-adjusted life year; WOMAC ¼Western Ontario and McMaster Universities Arthritis Index IACS ¼ intra-articular
corticosteroids; IAHA ¼ intra-articular hyaluronic acid
* ¼ symptomatic and complicated ulcers
y ¼ myocardial infarction and stroke
Strategies are ordered by increasing cost. The more expensive strategy is compared to the less expensive, non-dominated strategy.
ICER¼ Incremental Cost-Effectiveness Ratio, additional cost per additional quality-adjusted life year (QALY) gained comparing each non-dominant strategy with the nextmost
expensive, non-dominated strategy. Expressed in $/QALY
z ¼ treatment subject to dominance: another treatment is less expensive and more effective
x ¼ treatment subject to extended dominance: a combination of two other treatments is less expensive and more effective
Ratios may not be exactly reproducible with the numbers shown, due to rounding.
Figure 1. Decision Analytic Model. Squares represent decision nodes; cir-
cles represent chance nodes; triangles represent terminal nodes Clone 1
replicates the tree for all the other treatment strategies with their
respective model parameters.
Figure 2. Cost-effectiveness plane; A: Base-case analysis - Low risk cohort
(55-64 years). B: High risk cohort (65-74 years).
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A394ﬁndings clearly indicate that even in low-risk group, it is cost-effective
to co-prescribe PPIs along with traditional or COX-2-selective NSAIDs.
Our results should be interpreted with caution due to their short time
horizon and may not generalize beyond 3 months.
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COULD NERVE GROWTH FACTOR INHIBITORS HAVE A PLACE IN THE
TREATMENT OF KNEE OSTEOARTHRITIS?: IMPACT OF JOINT
DESTRUCTION AND MEANS OF ADMINISTRATION OSSN THE VALUE
OF TANEZUMABS
E. Losina y, G. Michl y, J. Collins y, D.J. Hunter z, J.M. Jordan x, E. Yelin k,
A.D. Paltiel ¶, J.N. Katz y. yBrigham and Women's Hosp., Boston, MA, USA;
zUniv. of Sydney, Sydney, Australia; xUNC Sch. of Med., Chapel Hill, NC,
USA; kUniv. of California, San Francisco, San Francisco, CA, USA; ¶Yale
Sch. of Publ. Hlth., New Haven, CT, USA
Purpose: Tanezumab is a nerve growth factor inhibitor in development
as an analgesic for patients with knee osteoarthritis (OA). While several
studies show promising pain relief with Tanezumab, reports of joint
destruction have led to temporary suspension of further studies. We
sought to establish cost and toxicity (joint destruction) thresholds that
would make Tanezumab a cost-effective treatment for moderate to
severe knee OA.
Methods:We used the Osteoarthritis Policy (OAPol) model, a validated
computer simulation model of the natural history and management of
knee OA, to estimate the cost-effectiveness of using Tanezumab in
patients with persistent pain despite currently available pharmacologic
therapy. Population characteristics and efﬁcacy were derived from Lane
et al. (2010). Mean age was 59 years, 59% were female and 88% were
white. Baseline WOMAC Pain (0-100, with 100¼worst) was 67 (SD 13).
Mean pain reduction from Tanezumabwas 34 (SD 20) in the ﬁrst year of
treatment. In the absence of long-term data, we estimated Tanezumab
annual discontinuation rate after the ﬁrst year at 10% using data on
Enbrel in RA. In the base case, we assumed joint destruction in 1% of
subjects based on data from Pﬁzer’s 2012 Arthritis Advisory Committee
Brieﬁng Document. In subjects with a destroyed joint, we assumed a
50% decrease in pain reduction and structural efﬁcacy for primary and
revision total knee replacement surgery (TKR). We included drug,
administration, and monitoring costs of Tanezumab. The price of one
dose of Tanezumab (delivered every 8 weeks) was varied from $200 to
$1,000. For each dose price, we considered self-administered subcuta-
neous injections vs. provider-administered IV infusion. The cost of an IV
infusion varies by setting (non-hospital vs. hospital) and by whether it
is billed as chemotherapy. Administrative costs therefore varied from $0
to $346 per dose in this analysis. Annual monitoring costs for IV infu-
sions were ﬁxed at $250 and included 2x/yr MD visits, 1x/yr blood tests,
and biannual X-rays to check for OA progression. Monitoring costs for
subcutaneous injections were $442, for two additional MD visits/yr.
Cost-effectiveness was estimated as the ratio of incremental costs to
incremental effectiveness (quality-adjusted life years, QALYs) when
Tanezumab was added to current treatment for knee OA prior to pri-
mary TKR. Costs and QALYs were discounted at 3% per year. We deﬁned
a program as “cost-effective” if its cost-effectiveness ratio was below
$100,000/QALY. In sensitivity analyses we varied efﬁcacy, discontinua-
tion, joint destruction rates and costs of Tanezumab.
Results: In the base case analysis, Tanezumab led to an additional 0.27
quality-adjusted life years. It reduced primary TKR utilization by 17%
and revision TKR utilization by 29%, and increased mean age at TKR
from 67 to 70 years. Green shading in the Table indicates scenarios in
which Tanezumab was cost-effective. Subcutaneous Tanezumab at
$600/dose remained cost-effective when efﬁcacy decreased by 20% and
when discontinuation increased to 20%. Subcutaneous Tanezumab at
$600/dose also remained cost-effective at a 2% joint destruction rate,
but not when the joint destruction rate was increased to 5%. At joint
destruction rates above 10%, Tanezumab decreased quality-adjusted life
expectancy and did not represent a viable treatment option.Conclusions: Tanezumab (a promising NGF inhibitor in development)
could be a cost-effective treatment for moderate to severe knee OA pain
depending on the price of the drug and the delivery means. The value of
Tanezumab depends on the rate of joint destruction.
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EFFECTS OF DOXYCYCLINE AS AN ADJUVANT THERAPY ON THE
WOMAC INDEX OF PATIENTS WITH PRIMARY KNEE
OSTEOARTHRITIS
S. Salman, A.M. Ahmed. Coll. of Med., Baghdad, Iraq
Purpose: To examine the short-term effects of doxycycline compared
with placebo on the WOMAC index (Western Ontario and McMaster
Universities) of knee osteoarthritis during a 3-month treatment course.
Methods:One hundred forty patients were enrolled in this randomized,
placebo-controlled, double blind study. Half the patients (70) were
randomly assigned to receive oral doxycycline capsule 100 mg twice
daily in the drug group and the other half received a starch containing
capsule (the placebo group). The efﬁcacy outcome measure was the
change in the WOMAC index.
Results: There were no signiﬁcant differences between the drug and
placebo groups in pain score at the baseline visit (P¼0.63) or at the ﬁrst
visit one month later (P¼0.29). However, at the second visit, there was a
signiﬁcant reduction in pain score in the drug group compared to both
placebo group (P¼0.028) and the baseline scores. At the third visit,
three months later, the difference between both groups became more
signiﬁcant (P¼0.013). Stiffness and physical function scores in all
comparisons in different visits showed no signiﬁcant differences
between both study groups.Mean WOMAC scores were reduced at each
visit compared to its baseline value in drug group compared to the
placebo group, and the reduction in mean score of baseline vs. third
visit was signiﬁcantly much higher in the treatment group (8.37±2.1)
vs. (3.83±3.1) respectively, P<0.001.
Conclusions: Doxycycline at the oral twice-daily dosage of 100 mg has
symptomatic beneﬁt in patients with primary osteoarthritis of the
knees in terms of pain reduction and total WOMAC score.
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MRI ANALYSIS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS;
TREATMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS WITH ORAL
SALMON CALCITONIN
M.A. Karsdal y, E.B. Dam z, I. Byrjalsen y, A. Bihlet y, J.R. Andersen y,
B.J. Riis y, P. Alexandersen x, A.-C. Bay-Jensen y, C. Christiansen y. ,
CSMC021C2301/2 investigatorsyNordic BioSci., Herlev, Denmark;
zBiomediq, Copenhagen, Denmark; xCCBR, Ballerup, Denmark
Purpose: To evaluate the structuremodiﬁcation efﬁcacy in two phase III
studies by MRI of Oral Salmon Calcitonin (sCT) in osteoarthritis (OA)
patients with moderate to severe knee pain and joint structural damage
classiﬁed as Kellgren-Lawrence 2-3.
Methods: This is the combined reporting of two randomized, double-
blind, multi-center, placebo-controlled trials (CSMC021C2301 and
CSMC021C2302), evaluating the efﬁcacy and safety of sCT in patients
with painful knee OA, enrolling 1,176 and 1,030 patients, respectively,
total of 2206, of which 858 were included in the MRI knee sub-
population (demographics table 1). sCT was formulated with a 5-CNAC
carrier (a molecule based on Eligen® technology). MRIs were acquired
at four investigator sites using a Turbo 3D T1 sequence on a 0.18T Esaote
scanner (40 FA, TR 50ms, TE 16ms, scan time 10 minutes, resolution
0.7mm x 0.7mm x 0.8mm). The sequence was optimized for cartilage
visualization. Cartilage volumes were automatically quantiﬁed in the
medial tibial and the medial femoral compartments using a computer-
based method (KneeIQ). The volume scores were corrected for scanner
drift. The subjects had painful knee OA with structural manifestations.
Study subjects were randomized (1:1) to oral sCT 0.8 mg twice daily or
placebo for 24 months. This is the ﬁrst reporting of the combined
studies on the ﬁrst secondary endpoint, MRI.
Results: At the 24 month endpoint there was a signiﬁcant protection of
MRI total cartilage volume loss (P<0.02) in CSMC021C2301 albeit not in
CSMC021C2302 (P¼0.67), and not combined, ﬁgure 1.
Conclusions: The present formulation of oral calcitonin did not provide
reproducible clinical beneﬁts in patients with symptomatic knee OA
(NCT00486434, NCT00704847). Other formulations of calcitonin
receptor agonists in a selected subpopulation ﬁtting the mode of action
